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Introduction: ERBB3, one of the four members of the ErbB family of receptor tyrosine kinases, plays an important
role in breast cancer etiology and progression. In the present study, we aimed to identify novel miRNAs that can
potentially target ERBB3 and their biological functions.
Method: The expression levels of miR-143/145 and target mRNA were examined by relative quantification RT-PCR,
and the expression levels of target protein were detected by Western blot. We used bioinformatic analyses to
search for miRNAs that can potentially target ERBB3. Luciferase reporter plasmids were constructed to confirm direct
targeting. Furthermore, the biological consequences of the targeting of ERBB3 by miR-143/145 were examined by
cell proliferation and invasion assays in vitro and by the mouse xenograft tumor model in vivo.
Results: We identified an inverse correlation between miR-143/145 levels and ERBB3 protein levels, but not
between miR-143/145 levels and ERBB3 mRNA levels, in breast cancer tissue samples. We identified specific
targeting sites for miR-143 and miR-145 (miR-143/145) in the 3’-untranslated region (3’-UTR) of the ERBB3 gene
and regulate ERBB3 expression. We demonstrated that the repression of ERBB3 by miR-143/145 suppressed the
proliferation and invasion of breast cancer cells, and that miR-143/145 showed an anti-tumor effect by negatively
regulating ERBB3 in the xenograft mouse model. Interestingly, miR-143 and miR-145 showed a cooperative
repression of ERBB3 expression and cell proliferation and invasion in breast cancer cells, such that the effects of the
two miRNAs were greater than with either miR-143 or miR-145 alone.
Conclusion: Taken together, our findings provide the first clues regarding the role of the miR-143/145 cluster as a
tumor suppressor in breast cancer through the inhibition of ERBB3 translation. These results also support the idea
that different miRNAs in a cluster can synergistically repress a given target mRNA.
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Breast cancer is the most common cancer and principle
cause of death from cancer in women worldwide [1,2].
The overexpression of the ErbB family of receptor tyrosine
kinases (RTKs) is thought to be important in the develop-
ment of breast cancer [3,4]. The ErbB family consists of
four closely related members, including ERBB1/EGFR,
ERBB2/HER2, ERBB3/HER3 and ERBB4/HER4 [3,4]. Lig-
and binding to the extracellular domain of ErbB receptors
results in the formation of homodimers or heterodimers.
Receptor dimerization is activated by the intrinsic tyrosine
kinase-mediated autophosphorylation of the receptors
within the cytoplasmic domain, and the phosphorylation
results in the recruitment of downstream effector proteins
that activate multiple signaling pathways, including the
mitogen-activated protein kinase (MAPK) and phosphoi-
nositide 3-kinase (PI3K) pathways [3,4]. Through these
molecular mechanisms, the ErbB family regulates the pro-
liferation, differentiation and survival of human breast epi-
thelial cells, and aberrant expression or activity of this
family has been strongly linked to the etiology of breast
cancer [3,4].
For many years, it was believed that the ERBB2 recep-
tor played a major role in the development and progres-
sion of breast malignancies [5-7]. ERBB2 is a therapeutic
target in breast tumors that overexpress the receptor.
However, an increasingly important role for the ERBB3
receptor in the genesis of breast cancer has emerged.
ERBB3 is frequently upregulated in breast cancer, and
overexpression of ERBB3 is positively associated with
metastasis, histological grade, tumor size and recurrence
[5-7]. ERBB3 has also been implicated in the develop-
ment of resistance to anti-estrogens and ErbB tyrosine
kinase inhibitors, such as tamoxifen and gefitinib, re-
spectively [5-7]. ERBB3 is distinct in that it is the only
member of the ErbB receptor family that lacks tyrosine
kinase activity. In this way, activation of this receptor is
achieved only through the formation of heterodimers
with EGFR, ERBB2 or ERBB4 [5-7]. Consistent with
this idea, the ERBB2/3 heterodimer has been demon-
strated to be an “oncogenic unit” and a key factor in the
proliferation and invasion of human breast cancer cells.
Furthermore, co-expression of ERBB2 and ERBB3 is sig-
nificantly associated with decreased patient survival [5-8].
ERBB3 is also unique among the ErbB family in its ability
to directly recruit and activate the PI3K/Akt signaling
pathway, which undoubtedly favors tumor growth and
progression [5-7].
Over the past decade, a novel class of small RNA mol-
ecules known as microRNAs (miRNAs) has emerged as
a major regulator of the initiation and progression of hu-
man cancers, including breast cancer [9,10]. miRNAs are
small (~22-nucleotide long), single-stranded noncoding
RNA molecules that negatively regulate gene expressionby binding to the 3’-untranslated region (3’-UTR) of target
mRNA molecules, which results in either degradation of
the transcript or inhibition of translational [11-13]. Many
miRNAs work in conjunction with one another to fine
tune protein expression on a global level. Thus, miRNAs
play a significant role in post-transcriptional gene regula-
tion. Importantly, recent studies indicate that the dysregu-
lation of miRNAs is associated with human malignancies
and suggest a causal role of miRNAs in cancer etiology.
miRNAs presumably have a role in cancer because they
can affect the translation and stability of targeted onco-
genes or tumor suppressors, which eventually influence
cellular physiology [14-16]. For example, miR-143 and
miR-145 (miR-143/145), which are located in a cluster
within the 5q32-33 chromosomal region, are downregu-
lated in many types of cancers, including colon cancer and
breast cancer [17,18]. miR-143 and miR-145 have been
shown to possess anti-tumorigenic activity, with involve-
ment in various cancer-related events such as prolifera-
tion, invasion and migration. The target genes of miR-143
identified and verified thus far are primarily MAPK signal-
ing molecules, such as ERK5 and KRAS [19,20]. Target
genes of miR-145 include Mucin-1 [21], RTKN [22],
c-Myc [23] and EGFR [24].
Although dysregulation of ERBB3 and miRNAs is as-
sociated with tumorigenesis in human breast cancer,
little is known about the natural miRNAs that act on
ERBB3. In this study, we found that ERBB3 protein
levels, but not mRNA levels, were upregulated in breast
cancer tissues in comparison to adjacent noncancerous
tissues. We hypothesized that the high levels of ERBB3
are a consequence of miRNA regulation, and we subse-
quently identified a cluster of miRNAs, including miR-
143 and miR-145, that directly target and regulate the
expression of ERBB3 protein in breast cancer cells. Fur-
thermore, we showed that miR-143/145 inhibited ERBB3
expression and consequently suppressed the prolifera-
tion and invasion of breast cancer cells.
Materials and methods
Human tissue
Breast cancer tissues and paired adjacent noncancerous
tissues were derived from patients undergoing a surgical
procedure at the Tianjin Medical University Cancer In-
stitute and Hospital (Tianjin, China). Both tumors and
noncancerous tissues were confirmed histologically. The
pathological type of each cancer was determined to be
infiltrating ductal carcinoma. Written consent was pro-
vided by all of the patients, and the Ethics Committee of
Tianjin Medical University Cancer Institute and Hospital
approved all aspects of this study. Tissue fragments were
immediately frozen in liquid nitrogen at the time of sur-
gery and stored at −80°C. The clinical features of the pa-
tients are listed in Additional file 1: Table S1.
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The human breast cancer cell line MCF-7 and MBA-
MD-231 were purchased from the Shanghai Institute of
Cell Biology, Chinese Academy of Sciences (Shanghai,
China). MCF-7 and MBA-MD-231 cells were cultured in
DMEM (Gibco, Carlsbad, CA, USA) supplemented with
10% fetal bovine serum (Gibco) in a humidified incuba-
tor at 37°C with 5% CO2.RNA isolation and quantitative RT-PCR
Total RNA was extracted from the cultured cells and tis-
sues using TRIzol Reagent (Invitrogen) according to the
manufacturer’s instructions. Assays to quantify mature
miRNAs were performed using Taqman microRNA probes
(Applied Biosystems, Foster City, CA) according to the
manufacturer’s instructions. Briefly, 1 μg of total RNA was
reverse-transcribed to cDNA using AMV reverse tran-
scriptase (TaKaRa, Dalian, China) and a stem-loop RT pri-
mer (Applied Biosystems). The reaction conditions were as
follows: 16°C for 30 min, 42°C for 30 min and 85°C for
5 min. Real-time PCR was performed using a TaqMan
PCR kit and an Applied Biosystems 7300 Sequence De-
tection System (Applied Biosystems). The reactions
were incubated in a 96-well optical plate at 95°C for
10 min, followed by 40 cycles of 95°C for 15 s and 60°C
for 1 min. All of the reactions were run in triplicate.
After the reactions were complete, the cycle threshold
(CT) data were determined using fixed threshold set-
tings, and the mean CT was determined from triplicate
PCRs. A comparative CT method was used to compare
each condition to the control reactions. U6 snRNA was
used as an internal control, and the relative amount of
miRNA normalized to U6 was calculated with the equa-
tion 2-ΔΔCT, in which ΔΔCT = (CT miRNA − CT U6)target −
(CT miRNA − CT U6)control.
To quantify ERBB3 and β-actin mRNA, 1 μg of total
RNA was reverse-transcribed to cDNA using Oligo d(T)
18 primers (TaKaRa) and ThermoScript reverse tran-
scriptase (Invitrogen). The reaction conditions were as
follows: 42°C for 60 min and 70°C for 10 min. Real-time
PCR was then performed with the RT product, and
these reactions included SYBR Green dye (Invitrogen)
and specific primers for ERBB3 and β-actin. The se-
quences of the primers were as follows: ERBB3 (sense):
5’-TTCCGAGATGGGCAACTCTC-3’; ERBB3 (antisense):
5’-CTTGCAGACTTCGTGACAGG-3’; β-actin (sense): 5’-
AGGGAAATCGTGCGTGAC-3’; and β-actin (antisense):
5’-CGCTCATTGCCGATAGTG-3’. The reactions were in-
cubated at 95°C for 5 min, followed by 40 cycles of 95°C
for 30 s, 60°C for 30 s and 72°C for 30 s. After the reactions
were complete, the CT values were determined by setting a
fixed threshold. The relative amount of ERBB3 mRNA was
normalized to β-actin.miRNA overexpression or knockdown
miRNA overexpression was achieved by transfecting cells
with a miRNA mimic (a synthetic RNA oligonucleotide
duplex mimicking miRNA precursor), whereas knockdown
was achieved by transfecting cells with a miRNA inhibitor
(a chemically modified single-stranded antisense oligo-
nucleotide designed to specifically target mature miRNA).
Synthetic RNA molecules, including pre-miR-143, pre-
miR-145, anti-miR-143, anti-miR-145 and scrambled nega-
tive control RNA (pre-miR-control and anti-miR-control),
were purchased from GenePharma (Shanghai, China).
MCF-7 cells were seeded in 6-well plates and transfected
with Lipofectamine 2000 (Invitrogen) on the following day
when the cells were approximately 70% confluent. For
overexpression of miRNAs, 100 pmol of pre-miR-143, 100
pmol of pre-miR-145 or 50 pmol of both pre-miR-143 and
pre-miR-145 were used. For knockdown of miRNAs, 100
pmol of anti-miR-143, 100 pmol of anti-miR-145 or 50
pmol of both anti-miR-143 and anti-miR-145 were used.
After 6 h, the medium was changed to DMEM that was
supplemented with 2% fetal bovine serum. The cells were
harvested 24 h or 48 h after the transfection for the isola-
tion of total RNA or protein, respectively.
Plasmid construction and siRNA interference assay
A mammalian expression plasmid (pReceiver-M02-ERBB3)
designed to specially express the full-length open reading
frame (ORF) of human ERBB3 without the miR-143/145–
responsive 3’-UTR was purchased from GeneCopoeia
(Germantown, MD, USA). An empty plasmid served as
a negative control. The siRNA (sequence: AAGAGCG
ACTAGACATCAAGC) targeting human ERBB3 was
designed and synthesized by Invitrogen (Carlsbad, CA,
USA). A scrambled siRNA (Invitrogen) was included as
a negative control. Overexpression plasmid or siRNA
were transfected into MCF-7 cells using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s in-
structions. Total RNA or protein was isolated 24 h or
48 h after transfection. The ERBB3 mRNA and protein
expression levels were assessed by quantitative RT-PCR
and western blotting.
Luciferase reporter assay
The entire 3’-UTR of human ERBB3 was amplified by
PCR using human genomic DNA as a template. The
PCR products were inserted into the p-MIR-reporter
plasmid (Ambion, Austin, TX, USA). The insertion was
confirmed to be correct by DNA sequencing. To test the
binding specificity, the sequences that interact with the
seed sequence of miR-143 and miR-145 were mutated
(from UUGGGAG to AACCCUC for the miR-143 bind-
ing site; and from UUGGGAG to AACCCUC for the
miR-145 binding site), and the mutant ERBB3 3’-UTR was
inserted into an equivalent luciferase reporter plasmid.
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6-well plates and co-transfected with 2 μg of firefly lu-
ciferase reporter plasmid, 2 μg of β-galactosidase (β-gal)
expression plasmid (Ambion), and equal amounts (100
pmol) of miR-143/145 mimic, inhibitor, or scrambled
negative control RNA using Lipofectamine 2000 (Invi-
trogen). The β-gal plasmid was used as a transfection
control. Cells were harvested 24 h after transfection and
analyzed for luciferase activity using a luciferase assay
kit (Promega, Madison, WI, USA).
Protein isolation and Western blotting
Cells or tissues were lysed in a RIPA lysis buffer (50 mM
Tris–HCl, 150 mM NaCl, 0.1% SDS, 1% NP-40, 0.25%
sodium deoxycholate and 1 mM EDTA, pH 8.0) with
freshly added protease inhibitor cocktail (Roche) for
30 min on ice and were then centrifuged at 16,000 × g at
4°C for 10 min. The supernatant was collected, and the
protein concentration was calculated with a BCA protein
assay kit (Thermo Scientific, Rockford, IL, USA). Pro-
teins were separated by SDS-PAGE (Bio-Rad). After
electrophoresis, the proteins were electrotransferred to
PVDF membranes (Bio-Rad) and then blocked with 5%
skim milk for 1 h. The membranes were then incubated
with primary antibodies at 4°C for 12 h. After three
washes in TBST, the membranes were incubated with
horseradish peroxidase-conjugated secondary antibody
for 1 h at room temperature. After three washes, the
membranes were incubated with the SuperSignal West
Pico chemiluminescence substrate (Pierce). The protein
levels were normalized by probing the same blots with
α-Tubulin antibody. Anti-ERBB3 and anti-α-Tubulin anti-
bodies were purchased from Abcam (ab34641; Cambridge,
MA) and Santa Cruz Biotechnology (B-7; CA, USA),
respectively.
Construction of miR-143/145 overexpression lentiviral
vector
A 300-bp fragment containing genomic miR-143 and
miR-145 sequences was generated by PCR amplification
from human DNA and subsequently cloned into the
Lenti-PacTM human immunodeficiency virus (HIV) ex-
pression packing system (Invitrogen). miR-143/145 over-
expression lentiviral vector was added to MCF-7 cells at
70% confluence in 6-well plates or 10-cm dishes at an
MOI of 10 together with polybrene at a final concentra-
tion of 5 μg/mL according to the manufacturer’s instruc-
tions. Cells were then harvested for quantitative RT-PCR,
Western blotting or animal experiments.
Cell proliferation assay
MCF-7 cells were plated at 5 × 104 cells per well in 96-
well plates and then incubated overnight in DMEM sup-
plemented with 10% FBS. Cells were collected 12, 24, 36,48 and 60 hours post-transfection. After transfection,
20 μL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazo-
lium bromide (MTT) (5 mg/mL) was added into a corre-
sponding test well and incubated for 4 h. The supernatant
was then discarded, and 150 μL of DMSO was added to
each well to dissolve the precipitate. Absorbance was mea-
sured at a wavelength of 490 nm.
Transwell invasion assay
Transwell invasion assays were performed using Matri-
gel Invasion Chambers (BD Biosciences, Bedford, MA)
with inserts containing an 8-μm pore-sized membrane
with a thin layer of Matrigel. MCF-7 cells were transfected
and harvested as mentioned above and were seeded at a
density of 5 × 106/well on the upper chamber with serum-
free DMEM. DMEM with 10% FBS was put into the lower
compartment as chemo-attractant. Cells were allowed to
invade for 48 hours. Remaining cells in the upper chamber
were scraped out with a cotton swap. Matrigel membranes
were fixed with ice-cold methanol and then stained with
0.1% crystal violet solution. The invaded cells were counted
by microscopic examination. Each experiment was per-
formed in triplicate and repeated twice.
Establishment of tumor xenografts in mice
Four-week-old male C57BL/6 J mice were purchased
from the Model Animal Research Center of Nanjing
University (Nanjing, China) and maintained under spe-
cific pathogen-free conditions at Nanjing University.
Untreated MCF-7 cells or MCF-7 cells infected with the
miR-143/145 overexpression lentiviral vector or trans-
fected with the ERBB3 expression plasmid were injected
subcutaneously into C57BL/6 J mice (1 × 107 cells per
mouse, 7 mice per group). Mice were sacrificed after
one month. After the tumors were separated from the
animals, the length, width and height of the tumors was
measured with digital calipers. The tumor weights were
then determined and the ellipsoid volume was calculated
using the following formula: Volume = π/6 × (length) ×
(width) × (height). All animal care and handling procedures
were performed in accordance with the National Institutes
of Health’s Guide for the Care and Use of Laboratory Ani-
mals and were approved by the Institutional Review Board
of Nanjing University (Nanjing, China).
Statistical analysis
All of the Western blot and Transwell invasion assay im-
ages are representative of at least three independent ex-
periments. Quantitative RT-PCR, the luciferase reporter
assay and the cell viability assay were performed in trip-
licate, and each experiment was repeated several times.
The results are presented as the means ± SE of at least
three independent experiments. Statistical analysis was
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level was set as p < 0.05.
Results
Upregulation of ERBB3 protein but not mRNA in breast
cancer tissues
We first determined the expression patterns of ERBB3 in
human breast cancer tissues. After measuring the protein
levels of ERBB3 in six pairs of breast cancer tissues and
corresponding noncancerous tissues, we found that ERBB3
protein levels were dramatically higher in the breast cancer
tissues (Figure 1A). However, although ERBB3 protein was
consistently upregulated in breast cancer, ERBB3 mRNA
levels did not differ significantly between the cancer and
noncancerous tissues (Figure 1B). This disparity between
protein and mRNA in ERBB3 expression in breast cancers
strongly suggests that a post-transcriptional mechanism is
involved in ERBB3 regulation.Figure 1 Inverse correlation between miR-143/145 levels and ERBB3 p
analysis of ERBB3 protein levels in six pairs of breast cancer tissue (BC) and
right panel: quantitative analysis. (B) Quantitative RT-PCR analysis of ERBB3
RT-PCR analysis of miR-143 and miR-145 levels in six pairs of BC and NC sa
by the interactions between the binding sites in the ERBB3 3’-UTR (top) an
hybrid is indicated. The seed recognition sites are denoted, and all nucleot
human, mouse and rat. * P < 0.05; ** P < 0.01; *** P < 0.001.Identification of conserved miR-143 and miR-145 target
sites within the 3’-UTR of ERBB3
One important mode of post-transcriptional regulation
is the repression of mRNA transcripts by miRNAs. miR-
NAs are therefore likely to play a biologically relevant
role in regulating ERBB3 expression in breast cancer.
Three computational algorithms, including TargetScan
[25], miRanda [26] and PicTar [27], were used in com-
bination to identify potential miRNAs that can target
ERBB3. Using these approaches, miR-143 and miR-145
were identified as candidate miRNAs. miR-143 and miR-
145 are two miRNAs that are located within the same
cluster, but they do not share sequence homology. Fur-
thermore, all three algorithms predicted that these miR-
NAs are regulators of ERBB3. miR-143 and miR-145
were thus selected for further experimental verification.
Interest in the miR-143/145 cluster was also supported
by the recent identification of these two miRNAs asrotein levels in human breast cancer tissues. (A) Western blot
noncancerous tissue (NC) samples. Left panel: representative image;
mRNA levels in six pairs of BC and NC samples. (C) Quantitative
mples. (D) Schematic description of the hypothetical duplexes formed
d miR-143/145 (bottom). The predicted free energy value of each
ides in these regions are highly conserved across species, including
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interactions between miR-143/145 and the targeting sites
within the 3’-UTR of ERBB3 are illustrated in Figure 1C.
One predicted hybridization was observed between both
miR-143 and miR-145 and the 3’-UTR of ERBB3.
Though the two targeting sites within the 3’-UTR of
ERBB3 were nearby one another, the sites were non-
overlapping. The minimum free energy values of the hy-
bridizations between miR-143 and ERBB3 and between
miR-145 and ERBB3 were −25.9 and −28.2 kcal/mol, re-
spectively, which are well within the range of genuine
miRNA-target pairs. Moreover, there was perfect base-
pairing between the seed region (the core sequence that
encompasses the first 2–8 bases of the mature miRNA)
and the cognate targets. Furthermore, the miR-143/145
binding sequences in the ERBB3 3’-UTR were highly
conserved across species.
Detection of an inverse correlation between miR-143/143
and ERBB3 levels in breast cancer tissues
miRNAs are generally thought to have expression pat-
terns that are opposite to that of their targets [11-13].
We next investigated whether miR-143/145 were in-
versely correlated with ERBB3 in breast cancer. After de-
termining the levels of miR-143 and miR-145 in the
same six pairs of breast cancer tissues and correspond-
ing noncancerous tissues, we showed that miR-143 and
miR-145 levels were indeed downregulated in breast
cancer tissues (Figure 1D). Thus, ERBB3 was determined
to be a miR-143/145 target, based on both computa-
tional predictions and the inverse correlation between
miR-143/145 levels and ERBB3 protein levels, but not
mRNA levels, in human breast cancer.
Validation of ERBB3 as a direct target of miR-143/145
The correlation between miR-143/145 and ERBB3 was
further examined by evaluating ERBB3 expression in the
human breast cancer cell line MCF-7 and MBA-MD-231
after overexpression or knockdown of miR-143/145. In
these experiments, overexpression was achieved by
transfecting cells with pre-miR-143 and/or pre-miR-145,
which are synthetic RNA oligonucleotides that mimic
the miR-143 and miR-145 precursors. Knockdown of
miR-143/145 was achieved by transfecting cells with
anti-miR-143 and/or anti-miR-145, which are chemically
modified antisense oligonucleotides that are designed
to specifically target mature miR-143 and miR-145.
The efficient overexpression and knockdown of miR-
143/145 in MCF-7 cells are shown in Additional file 1:
Figure S1A and B. Cellular miR-143/145 levels were
increased approximately 400-fold when MCF-7 cells
were transfected with pre-miR-143/145, and these levels
dropped to approximately 20% of the normal level when
MCF-7 cells were treated with anti-miR-143/145. Asanticipated, overexpression of miR-143 or miR-145 sig-
nificantly suppressed ERBB3 protein levels in MCF-7
cells (Figure 2A). Interestingly, co-treatment of cells with
both pre-miR-143 and pre-miR-145 enhanced the sup-
pressive effect on ERBB3 protein expression compared
to treatments with either pre-miR-143 or pre-miR-145
alone (Figure 2A). These results indicated that the sup-
pressive effects of miR-143 and miR-145 on ERBB3 pro-
tein expression was not an individual response but was
instead a synergistic effect. Furthermore, the expression
of ERBB3 protein was significantly increased in MCF-7
cells transfected with anti-miR-143 or anti-miR-145, and
the greatest increase in expression occurred when both
anti-miR-143 and anti-miR-145 were used simultan-
eously (Figure 2A). These results further supported a
synergistic effect of miR-143 and miR-145 on ERBB3
downregulation in MCF-7 cells. To demonstrate the ro-
bust of the test, we repeated the above experiments in
additional breast cancer cell line, MBA-MD-231. miR-
143/145 levels were significantly increased when MBA-
MD-231 cells were transfected with pre-miR-143/145,
but their levels were unchanged when MBA-MD-231
cells were treated with anti-miR-143/145 (Additional
file 1: Figure S1C and D), which may be due to the low
expression level of miR-143/145 in MBA-MD-231 cells.
Consistent with the cellular levels of miR-143/145 after
transfection, ERBB3 protein levels were downregulated
when MBA-MD-231 cells were treated with pre-miR-
143/145, but their levels were unaffected by treatment
with anti-miR-143/145 (Figure 2B). To determine the
regulatory level at which miR-143/145 influenced ERBB3
expression, we repeated the above experiments and
examined the expression of ERBB3 mRNA after trans-
fection. Overexpression or knockdown of miR-143/145
did not affect ERBB3 mRNA stability in MCF-7 and
MBA-MD-231 cells (Figure 2C and D). These results
demonstrated that miR-143/145 specifically regulate
ERBB3 expression at the post-transcriptional level, which
is the most common mechanism for animal miRNAs.
To determine whether the negative regulatory effects
of miR-143/145 on ERBB3 expression were mediated
through the binding of miR-143/145 to the presumed
sites in the 3’-UTR of the ERBB3 mRNA, the full length
3’-UTR of ERBB3 containing the two presumed miR-
143/145 binding sites was placed downstream of the
firefly luciferase gene in a reporter plasmid. The result-
ing plasmid was transfected into MCF-7 cells along with
a transfection control plasmid (β-gal) and either pre-
miR-143/145, anti-miR-143/145 or scrambled negative
control RNAs. As expected, the luciferase activity was
markedly reduced in cells transfected with pre-miR-143
or pre-miR-145, and the potency was increased when
pre-miR-143 and pre-miR-145 were used in combination
(Figure 2E). In contrast, the luciferase activity was
Figure 2 miR-143/145 directly regulate ERBB3 expression at the post-transcriptional level. (A and B) Western blot analysis of ERBB3 protein
levels in MCF-7 (A) and MBA-MD-231 (B) cells treated with pre-miR-control, pre-miR-143, pre-miR-145 or both pre-miR-143 and pre-miR-145 and in
cells treated with anti-miR-control, anti-miR-143, anti-miR-145 or both anti-miR-143 and anti-miR-145. Left panel: representative image; right
panel: quantitative analysis. (C and D) Quantitative RT-PCR analysis of ERBB3 mRNA levels in MCF-7 (C) and MBA-MD-231 (D) cells treated with
pre-miR-control, pre-miR-143, pre-miR-145 or both pre-miR-143 and pre-miR-145 and in cells treated with anti-miR-control, anti-miR-143,
anti-miR-145 or both anti-miR-143 and anti-miR-145. (E) Direct recognition of the ERBB3 3’-UTR by miR-143/145. MCF-7 cells were co-transfected
with firefly luciferase reporters containing either wild-type (WT) or mutant (Mut) miR-143/145 binding sites in the ERBB3 3’-UTR and pre-miR-control,
pre-miR-143, pre-miR-145 or both pre-miR-143 and pre-miR-145, or with anti-miR-control, anti-miR-143, anti-miR-145 or both anti-miR-143 and
anti-miR-145. Twenty-four hours after transfection, the cells were assayed using a luciferase assay kit. The results are displayed as the ratio of firefly
luciferase activity in the miR-143/145-transfected cells to the activity in the control cells. * P < 0.05; ** P < 0.01.
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anti-miR-143 or anti-miR-145, and a maximal increase
in activity was observed when cells were transfected
simultaneously with both anti-miR-143 and anti-miR-
145 (Figure 2E). Furthermore, we introduced point mu-
tations into the corresponding complementary sites in
the 3’-UTR of ERBB3 to eliminate the predicted miR-
143/145 binding sites. This mutated luciferase reporter
was unaffected by either overexpression or knockdown
of miR-143/145 (Figure 2E). This finding suggested thatthe miRNA binding sites strongly contributed to the
miRNA:mRNA interaction that mediated the post-
transcriptional repression of ERBB3 expression. Inter-
estingly, co-treatment with both miR-143 and miR-145
at the same time suppressed the luciferase reporter
containing the miR-143/145–responsive 3’-UTR to a
greater extent than when either miR-143 or miR-145
was introduced alone. In conclusion, our results dem-
onstrated that miR-143/145 directly recognized and
bound to the 3’-UTR of the ERBB3 mRNA transcript
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breast cancer cells.
Co-treatment with miR-143 and miR-145 synergistically
suppress proliferation and invasion in breast cancer cells
We next analyzed the biological consequences of the de-
creased expression of miR-143 and miR-145 in breast
cancer cells. We evaluated the effects of miR-143 and
miR-145 on the proliferation and invasion of MCF-7 and
MBA-MD-231 cells using the MTT and the Transwell
invasion assays. In support of the notion that miR-143
and miR-145 function as tumor suppressive miRNAs [9],
MCF-7 and MBA-MD-231 cells transfected with pre-
miR-143/145 showed decreased proliferation; in con-
trast, knockdown of miR-143/145 had the opposite effect
on cell proliferation (Figure 3A and B; left and middle
panel). The Transwell invasion assay showed that the
percentage of invaded cells was significantly lower in
MCF-7 and MBA-MD-231 cells transfected with pre-
miR-143/145 and higher in cells transfected with anti-
miR-143/145 (Figure 3C-F; upper and middle panel).
Meanwhile, although miR-143 and miR-145 can indi-
vidually suppress cell proliferation and invasion, the sim-
ultaneous introduction of both miR-143 and miR-145
showed a cooperative repression of cell proliferation and
invasion compared to effects of either miR-143 or miR-
145 alone. These results demonstrated that miR-143 and
miR-145 synergistically suppress proliferation and inva-
sion in breast cancer cells.
miR-143 and miR-145 suppress proliferation and invasion
of breast cancer cells by targeting ERBB3
We next analyzed the biological consequences of the
miR-143/145-driven repression of ERBB3 expression in
breast cancer cells. We first investigated whether the
overexpression or knockdown of ERBB3 would have an
impact on cell proliferation and invasion in MCF-7 and
MBA-MD-231 cells. To knock down ERBB3, a siRNA
targeting ERBB3 was designed and then transfected into
MCF-7 and MBA-MD-231 cells. To overexpress ERBB3,
an expression plasmid designed to specifically express
the full-length ORF of ERBB3 without the miR-143/
145-responsive 3’-UTR was also constructed and trans-
fected into MCF-7 and MBA-MD-231 cells. Efficient
knockdown and overexpression of ERBB3 in MCF-7
and MBA-MD-231 cells is shown in Additional file 1:
Figure S2A, D, Figure S3A and D. Consistent with pre-
vious studies showing that ERBB3 functions as an
oncogene [5-7], MCF-7 and MBA-MD-231 cells trans-
fected with the ERBB3 overexpression plasmid prolifer-
ated at a significantly higher rate (Additional file 1:
Figure S2E and Figure S3E), whereas siRNA-mediated
knockdown of ERBB3 decreased proliferation (Additional
file 1: Figure S2B and Figure S3B). Similarly, MCF-7 andMBA-MD-231 cells transfected with the ERBB3 overex-
pression plasmid showed a stimulation of cell invasion
(Additional file 1: Figure S2F and Figure S3F), and knock-
down of ERBB3 with siRNAs significantly inhibited cell in-
vasion (Additional file 1: Figure S2C and Figure S3C).
Moreover, compared to MCF-7 and MBA-MD-231 cells
transfected with pre-miR-143/145, the cells transfected
with pre-miR-143/145 and the ERBB3 overexpression
plasmid exhibited significantly higher proliferation rates
(Figure 3A and B; right panel), suggesting that miR-143/
145–resistant ERBB3 rescued the suppression of ERBB3
by miR-143/145 and attenuated the anti-proliferative
effect of miR-143/145. Likewise, when MCF-7 and MBA-
MD-231 cells were simultaneously transfected with pre-
miR-143/145 and the ERBB3 overexpression plasmid,
ERBB3 dramatically rescued the suppressive effect of
miR-143/145 on cell invasion (Figure 3C-F; lower panel).
These results demonstrated that ERBB3 is crucial to the
proliferation and invasion of breast cancer cells, and that
miR-143/145 can inhibit these cell functions through the
silencing of ERBB3.
miR-143 and miR-145 decrease the growth rate of breast
cancer cells in vivo
We next evaluated the effects of miR-143 and miR-145
overexpression on the growth of human breast cancer
cell xenografts in mice. The use of viral constructs of-
fered the possibility of rapidly producing high intracellu-
lar levels of mature miRNA via the endogenous miRNA
processing pathway. To generate viral expression con-
structs, 300-bp fragments containing the genomic se-
quences of miR-143 and miR-145 were obtained by PCR
amplification of human DNA and were then cloned into
a lentiviral expressing vector. When MCF-7 cells were
infected with these viral vectors, the expression of ma-
ture miR-143 and miR-145 was found to be 4–6-fold
higher than the endogenous miRNA levels (Additional
file 1: Figure S1E), and ERBB3 protein expression was
significantly inhibited (Additional file 1: Figure S1F).
MCF-7 cells were also transfected with an ERBB3 ex-
pression plasmid. MCF-7 cells (1 × 107 cells per 0.1 mL)
with elevated miR-143/145 or ERBB3 levels were im-
planted subcutaneously into 4-week-old C57/BL6 mice,
and tumor growth was then evaluated at day 28 after cell
implantation (Figure 4A). We observed a significant and
marked reduction in the sizes and weights of the tumors
in the miR-143/145-overexpressing group compared to
control group, whereas the size and weight of the tu-
mors in the ERBB3-overexpressing group was increased
(Figure 4B and C). Total RNA was subsequently ex-
tracted from each xenograft and was used to evaluate
the expression of mature miR-143 and miR-145. After
28 days of xenograft growth in vivo, tumors from the
miR-143/145-overexpressing group showed a significant
Figure 3 (See legend on next page.)
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Figure 3 miR-143/145 regulate proliferation and invasion of breast cancer cells by targeting ERBB3. (A and B) MTT viability assays
were performed 12, 24, 36, 48 and 60 h after the transfection of MCF-7 (A) and MBA-MD-231 (B) cells with pre-miR-control, pre-miR-143,
pre-miR-145 or pre-miR-143/145 (left panel), or with anti-miR-control, anti-miR-143, anti-miR-145 or anti-miR-143/145 (middle panel), or with
either pre-miR-control, pre-miR-143/145 or both pre-miR-143/145 and the ERBB3 overexpression vector (right panel). (C-F) Transwell invasion
assays were performed after the transfection of MCF-7 (C and D) and MBA-MD-231 (E and F) cells with pre-miR-control, pre-miR-143, pre-miR-145 or
pre-miR-143/145 (upper panel), or with anti-miR-control, anti-miR-143, anti-miR-145 or anti-miR-143/145 (middle panel), or with either pre-miR-control,
pre-miR-143/145 or both pre-miR-143/145 and the ERBB3 overexpression vector (lower panel). C and E: representative image; D and F: quantitative
analysis. * P < 0.05; ** P < 0.01.
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miR-145 compared to tumors from the control group
(Figure 4D). We also extracted total RNA and protein
from each xenograft and evaluated the steady-state levels
of ERBB3 by quantitative RT-PCR and Western blotting.
Our results showed that ERBB3 mRNA levels were un-
changed in the tumors from the miR-143/145-overex-
pressing group but increased in tumors from the
ERBB3-overexpressing group (Figure 4E). Moreover,
tumors from the miR-143/145-overexpressing group
displayed reduced ERBB3 protein levels compared to tu-
mors from the control group, whereas the tumors from
the ERBB3-overexpressing group showed elevated
ERBB3 protein levels (Figure 4F). These results were
consistent with the findings of the in vitro assays, which
firmly validated the biological role of miR-143/145 in
breast tumorigenesis through the targeting of ERBB3.
Discussion
Over the past decade, major advances in our comprehen-
sion of breast cancer biology have led to improved diag-
nostic and prognostic techniques and to the development
of novel targeted therapies. However, the efficacy of new
treatments remains limited by a combination of drug re-
sistance and our limited understanding of tumor cell sig-
naling pathways. Recently, an important role for the
ERBB3 receptor in the genesis and progression of breast
cancer has emerged [5-7]. ERBB3 is frequently overex-
pressed in breast cancer and tends to function as an onco-
genic unit by forming heterodimers with ERBB2 [5-7].
Thus, ERBB3 offers a particularly promising molecular
target for breast cancer therapy. However, very little is
known about the regulation of ERBB3 expression in breast
cancer. Thus, the molecular mechanisms underlying
ERBB3 regulatory pathways need to be fully elucidated.
In this study, we predicted that ERBB3 is a target of
miR-143 and miR-145, which are a cluster of miRNAs
that have been reported in many studies to be downreg-
ulated and to function as tumor suppressors in most
cancers [17,18]. After measuring the expression levels of
miR-143/145 and ERBB3 in human breast cancer tissue
and paired noncancerous tissue, we detected an inverse
correlation between miR-143/145 levels and ERBB3 pro-
tein levels. Furthermore, by overexpressing or knockingdown miR-143/145 in MCF-7 cells, we experimentally
validated that miR-143/145 directly inhibited ERBB3
translation. Finally, we showed that miR-143/145 inhib-
ited ERBB3 expression and consequently promoted the
proliferation and invasion of breast cancer cells, both
in vitro and in vivo. The results delineate a novel regula-
tory network employing miR-143/145 and ERBB3 to
fine-tune cell proliferation and invasion. We also pro-
vided evidence that restoration of ERBB3 expression can
reverse miR-143/145-suppressed cell proliferation and
invasion, suggesting that the targeting of ERBB3 is one
mechanism by which the miR-143/145 cluster exerts its
tumor suppressive function. Therefore, the modulation
of ERBB3 by miR-143/145 may explain why the down-
regulation of miR-143/145 during breast carcinogenesis
can promote cancer progression.
miRNAs can be grouped into families and clusters based
on sequence and genomic location, respectively. miRNA
family members are composed of multiple monocistronic
miRNAs that have primary sequence similarity with the
same seed sequence. Because the seed sequence contrib-
utes significantly to mRNA target specificity, miRNA fam-
ily members are often thought to have extensive mRNA
target overlap and redundant functions. On the other
hand, miRNAs that are located nearby in the genome
(within 10 kb) are considered to belonging to a single
cluster. miRNA clusters are transcribed coordinately as
polycistronic units that are processed to produce the indi-
vidual members, which result in co-expression of the miR-
NAs. miRNAs originating from a single cluster often
display corresponding sequence homology (e.g., miR-15a
and miR-16) and therefore possess overlapping targets.
However, for miRNAs in a cluster that do not share hom-
ology (e.g., miR-143 and miR-145), their individual and
combined functionalities are less clear. One goal of this
study was to determine whether miR-143 and miR-145
function individually or synergistically. In our study, bio-
informatic analyses of the 3’-UTR of ERBB3 revealed two
non-overlapping target elements for miR-143 and miR-
145. Experimental validations supported the hypothesis
that miR-143 and miR-145 exhibited a cooperative repres-
sion of ERBB3 expression and luciferase activity that was
stronger than with either miR-143 or miR-145 alone. As
a result, co-treatment with both miR-143 and miR-145
Figure 4 (See legend on next page.)
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Figure 4 Effects of overexpression of miR-143/145 or ERBB3 on the growth of breast cancer cell xenografts in mice. (A) Flow chart of
the experimental design. MCF-7 cells were either infected with a lentiviral expression vector to express miR-143 and miR-145 or transfected
with an ERBB3 plasmid to overexpress ERBB3. MCF-7 cells (1 × 107 cells per 0.1 mL) with increased miR-143/145 or ERBB3 levels were then
implanted subcutaneously into 4-week-old C57/BL6 mice (7 mice per group), and tumor growth was evaluated at day 28 after cell implantation.
(B) Representative image of the tumors from mice implanted with the control MCF-7 cells, the miR-143/145-overexpressing MCF-7 cells or the
ERBB3-overexpressing MCF-7 cells. (C) Quantitative analysis of the tumor weights from mice implanted with control MCF-7 cells, miR-143/
145-overexpressing MCF-7 cells or ERBB3-overexpressing MCF-7 cells. (D) Quantitative RT-PCR analysis of miR-143 and miR-145 levels in the
tumors from the mice implanted with control MCF-7 cells, miR-143/145-overexpressing MCF-7 cells or ERBB3-overexpressing MCF-7 cells.
(E) Quantitative RT-PCR analysis of ERBB3 mRNA levels in the tumors from mice implanted with control MCF-7 cells, miR-143/145-overexpressing
MCF-7 cells or ERBB3-overexpressing MCF-7 cells. (F) Western blotting analysis of ERBB3 protein levels in the tumors from mice implanted
with control MCF-7 cells, miR-143/145-overexpressing MCF-7 cells or ERBB3-overexpressing MCF-7 cells. Left panel: representative image; right
panel: quantitative analysis. * P < 0.05; ** P < 0.01.
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breast cancer cells compared with a single treatment with
either miR-143 or miR-145. Because there are currently
very few demonstrations of clusters of non-family miR-
NAs that target the same genes, our results provide novel
evidence that individual miRNAs within a cluster that dis-
play a co-expression pattern but lack sequence homology
can simultaneously and cooperatively repress a given tar-
get mRNA. Thus, although a single miRNA can clearly
produce a phenotypic disturbance, when multiple miR-
NAs work in concert to repress a gene the effect may be
more efficient and potent.
miRNAs are aberrantly expressed or mutated in can-
cer, which suggests a role for miRNAs as a novel class of
oncogenes or tumor suppressor genes [14,16]. Given the
involvement of miRNAs in cancer development, the ma-
nipulation of cellular miRNA levels has emerged as a po-
tential therapeutic strategy. Efforts to predictably alter
intracellular transcript profiles by increasing specific
miRNA levels through either transfection or viral deliv-
ery methods have demonstrated the potential of this
strategy to modulate cellular physiology [28]. Conversely,
attempts to reduce miRNA levels using biologically
stable antisense oligonucleotides such as antagomirs
have also proven capable of altering intracellular tran-
script profiles [29]. In this study, co-treatment with miR-
143 and miR-145 showed a synergistic anti-tumor effect
both in vitro and in vivo through the negative regulation
of ERBB3 in human breast cancer. We hypothesize that
a combination replacement treatment with both miR-
143 and miR-145 will be a promising strategy for cancers
showing downregulation of miR-143 and miR-145. In fu-
ture studies, an effective drug delivery system needs to
be developed for the application of miR-143 and miR-
145 for breast cancer therapy.
Intense efforts have been made to inhibit the activities
of the ERBB1/EGFR and ERBB2/HER2 receptors in can-
cer patients by designing antibodies against the ligand
binding domains or small molecules against the tyrosine
kinase domains. Both approaches have shown consider-
able clinical promise. However, increasing evidencesuggests that the majority of cancer patients do not re-
spond to these therapies, and those who do show an ini-
tial response ultimately become refractory to treatment
[30]. ERBB3 has recently been proposed to be involved
in the acquired resistance to ErbB-targeted drugs [30].
ERBB3 limits the impact of exclusively targeting ERBB1/
EGFR or ERBB2/HER2 and provides a route for acquired
resistance to anti-cancer drugs that inhibit ErbBs. Along
with the biological impact of ERBB3 signaling on
ERBB2-amplified breast cancer, active ERBB3 is a means
of escape from therapeutic suppression by several tyro-
sine kinase inhibitors [30]. Thus, ERBB3 is likely to be-
come a focus of breast cancer treatment. Recent studies
have linked the acquisition of cancer drug resistance to
the altered expression of miRNAs [31]. miR-143 and
miR-145 have frequently been reported to be involved in
drug resistance in many cancer types, although little evi-
dence has been detected in breast cancer. Future studies
are required to investigate whether miR-143 and miR-
145 are involved in the mechanism of resistance to
ErbB-targeted drugs in breast cancer. Because the target-
ing of ERBB3 has the potential to enhance the efficacy of
other RTK inhibitors, combinatory treatments with both
miR-143/145 and ErbB-targeted drugs may offer a viable
strategy for breast cancer therapy. Future studies are ne-
cessary to address the clinical feasibility of implementing
miRNA-based approaches to modulate sensitivity to che-
motherapeutic agents.
Taken together, our results not only reveal a critical
role for miR-143 and miR-145 as tumor suppressors in
breast carcinogenesis through repression of ERBB3
translation but also show that different miRNAs within a
cluster can simultaneously and cooperatively repress a
given target mRNA. This study may provide a potential
new target for future breast cancer therapy.
Conclusions
Taken together, our results not only reveal a critical role
for miR-143 and miR-145 as tumor suppressors in breast
carcinogenesis through repression of ERBB3 translation
but also show that different miRNAs within a cluster
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get mRNA. This study may provide a potential new tar-
get for future breast cancer therapy.
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